News | August 31, 2025
Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Subscribe To Our Newsletter & Stay Updated
